Cancer Immunotherapy

Multiple studies have established that elevated expression of galectin-3 correlates with aggressiveness and relapse in multiple human cancers, making it an attractive target for cancer therapy. Publications on the role of galectins in cancer can be found here.

We believe that due to its unique ability to bind and sequester galectin-3, GCS-100 has the potential to be a unique therapy for the treatment of cancer. Published studies provide evidence that the targeted inhibition by GCS-100 of the actions of galectin-3 results in important anti-cancer properties, including aActivation of innate immune response to cancer cells (activation of anergic T-cells)

Publications on the use of GCS-100 can be found here.

Activation of Immune Response to Cancer Cells
(Activation of Anergic T-Cells)

The adaptive immune system is the body’s first line of defense against pathogens and disease T-cells represent the body’s natural defense against cancer and increased concentration of T-cells within a tumor normally equates to better outcome. However, in some cancer patients, T-cell activity is diminished. This diminished activity observed in T-cells was linked to a dissociation between the T-cell receptor and its co-receptor CD8. This disassociation was linked to “trapping” of the T-cell receptor in a galectin-3 lattice of glycoproteins at the cell surface.

Exciting new research has also shown that galectin-3 antagonists can reverse T-cell inactivation by disruption of this lattice. In particular, GCS-100 was found to be effective at restoring T-cell activity.

GCS-100 Restores Function of Anergic Tumor-Infiltrating
Lymphocytes ex vivo

 

Control – Untreated cells, G-3 Ab – aniti-galectin-3 specific antibody
Source: Derived from Dermotte et al. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice, Cancer Research, Oct 1, 2010 70 (19), pgs. 7476-7488

GCS-100 Promotes Survival of Tumor Bearing Mice by Reversing
Galectin-3 Mediated T-Cell Suppression

Source: Dermotte et al. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice, Cancer Research, Oct 1, 2010 70 (19), pgs. 7476-7488